Physician profile
Kelsi Dillon
NPI 1598470452
$1,781.80
in general payments reported to CMS, 2019-2025
22 companies · $814 in 2025
The $814 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $450 · 2024: $517 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,638 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,637.80 |
| Education | $144.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $394.11 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $280.42 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $148.03 | 2023-2025 | Mounjaro, Jardiance, Emgality |
| Astellas Pharma US INC | $115.33 | 2025 | Veozah |
| Corcept Therapeutics | $73.20 | 2025 | Korlym |
| Exact Sciences Corporation | $70.86 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $69.29 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.85 | 2023-2025 | Jardiance |
| Pfizer INC. | $64.60 | 2023-2024 | |
| Edwards Lifesciences Corporation | $56.20 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Aimmune Therapeutics, INC. | $55.08 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $53.45 | 2023-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.02 | 2023-2025 | Caplyta |
| Alkermes, INC. | $48.81 | 2025 | Aristada, Lybalvi |
| Novo Nordisk INC | $45.04 | 2023-2025 | Wegovy, Ozempic |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $42.28 | 2023-2025 | |
| Organon LLC | $34.66 | 2023 | Nexplanon |
| Glaxosmithkline, LLC. | $31.86 | 2025 | Trelegy Ellipta, Arexvy |
| Viatris Specialty LLC | $25.15 | 2025 | Yupelri |
| Sanofi-Aventis U.S. LLC | $19.61 | 2025 | |
| Hologic Sales and Service, LLC | $19.24 | 2023 | Thinprep 2000 Processor, Aptima |
| Amgen INC. | $13.71 | 2023 | Prolia, Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsi Dillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.